Pseudo-acute kidney injury secondary to tepotinib

Veerle Wijtvliet^{1

2}, Laurence Roosens³, Charlotte De Bondt⁴, Annelies Janssens⁴, Daniel Abramowicz^{1

2}

Affiliations

¹ Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium.
² Laboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
³ Department of Clinical Biology, Antwerp University Hospital, Antwerp, Belgium.
⁴ Department of Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium.

Veerle Wijtvliet et al. Clin Kidney J. 2022.

. 2022 Aug 1;16(4):760-761.

doi: 10.1093/ckj/sfac180. eCollection 2023 Apr.

Veerle Wijtvliet^{1

2}, Laurence Roosens³, Charlotte De Bondt⁴, Annelies Janssens⁴, Daniel Abramowicz^{1

2}

¹ Department of Nephrology and Hypertension, Antwerp University Hospital, Antwerp, Belgium.
² Laboratory of Experimental Medicine and Pediatrics and member of the Infla-Med Centre of Excellence, University of Antwerp, Antwerp, Belgium.
³ Department of Clinical Biology, Antwerp University Hospital, Antwerp, Belgium.
⁴ Department of Thoracic Oncology, Antwerp University Hospital, Antwerp, Belgium.

No abstract available

Conflict of interest statement

The authors have no conflicts of interest. Furthermore, this article has not been published previously in whole or part.

1. Socinski MA, Pennell NA, Davies KD. MET exon 14 skipping mutations in non-small-cell lung cancer: an overview of biology, clinical outcomes, and testing considerations. JCO Precis Oncol 2021;5:653–63 - PMC - PubMed
1. Mohan A, Herrmann SM. Capmatinib-induced pseudo-acute kidney injury: a case report. Am J Kidney Dis 2022;79:120–4 - PubMed